CBD! WTH? References

Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics, 12(4), 825–836. https://doi.org/10.1007/s13311-015-0387-1

Commissioner, O. of the. (n.d.). Press Announcements – FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy [WebContent]. Retrieved October 13, 2018, from https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm

Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L. S., Martin-Santos, R., … Hallak, J. E. C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology (Oxford, England), 25(1), 121–130. https://doi.org/10.1177/0269881110379283

de Mello Schier, A. R., de Oliveira Ribeiro, N. P., Coutinho, D. S., Machado, S., Arias-Carrión, O., Crippa, J. A., … Silva, A. C. (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS & Neurological Disorders Drug Targets, 13(6), 953–960.

Fasinu, P. S., Phillips, S., ElSohly, M. A., & Walker, L. A. (2016). Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 36(7), 781–796. https://doi.org/10.1002/phar.1780

Fine, P. G., & Rosenfeld, M. J. (2013). The Endocannabinoid System, Cannabinoids, and Pain. Rambam Maimonides Medical Journal, 4(4). https://doi.org/10.5041/RMMJ.10129
Fischer, B., Kuganesan, S., & Room, R. (2015). Medical Marijuana programs: Implications for cannabis control policy – Observations from Canada. International Journal of Drug Policy, 26(1), 15–19. https://doi.org/10.1016/j.drugpo.2014.09.007

Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics, 133(1), 79–97. https://doi.org/10.1016/j.pharmthera.2011.09.002

Hill, K. P., Palastro, M. D., Johnson, B., & Ditre, J. W. (2017). Cannabis and Pain: A Clinical Review. Cannabis and Cannabinoid Research, 2(1), 96–104. https://doi.org/10.1089/can.2017.0017

Onaivi, E. S., Green, M. R., & Martin, B. R. (1990). Pharmacological characterization of cannabinoids in the elevated plus maze. The Journal of Pharmacology and Experimental Therapeutics, 253(3), 1002–1009.

Pamplona, F. A., da Silva, L. R., & Coan, A. C. (2018). Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., … Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, 175, 133–150. https://doi.org/10.1016/j.pharmthera.2017.02.041

Russo, E. B. (2018). Cannabis Therapeutics and the Future of Neurology. Frontiers in Integrative Neuroscience, 12. https://doi.org/10.3389/fnint.2018.00051

Silvestri, C., & Di Marzo, V. (2013). The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders. Cell Metabolism, 17(4), 475–490. https://doi.org/10.1016/j.cmet.2013.03.001

Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacology (Oxford, England), 7(1 Suppl), 82–88. https://doi.org/10.1177/026988119300700112